INSIGHT 2 Trial Results
INSIGHT 2: Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib

Released: June 09, 2023

Activity

Progress
1
Course Completed